

Yuko Kono

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6872743/publications.pdf>

Version: 2024-02-01

55
papers

3,846
citations

172457

29
h-index

168389

53
g-index

55
all docs

55
docs citations

55
times ranked

4049
citing authors

#	ARTICLE	IF	CITATIONS
1	Liver transplantation for hepatocellular carcinoma following checkpoint inhibitor therapy with nivolumab. American Journal of Transplantation, 2022, 22, 1699-1704.	4.7	33
2	GlycoFibroTyper: A Novel Method for the Glycan Analysis of IgG and the Development of a Biomarker Signature of Liver Fibrosis. Frontiers in Immunology, 2022, 13, 797460.	4.8	10
3	Eliciting Patient Preferences for Hepatocellular Carcinoma Screening: A Choice-Based Conjoint Analysis. Journal of the American College of Radiology, 2022, 19, 502-512.	1.8	3
4	Liver imaging: it is time to adopt standardized terminology. European Radiology, 2022, 32, 6291-6301.	4.5	13
5	Contrast-enhanced Ultrasound (<scp>CEUS</scp>) in the Evaluation of Hemoperitoneum in Patients With Cirrhosis. Journal of Ultrasound in Medicine, 2022, , .	1.7	2
6	Using LI-RADS With Contrast-enhanced Ultrasound. Clinical Liver Disease, 2021, 17, 154-158.	2.1	2
7	Using Contrast-enhanced Ultrasound to Characterize Focal Liver Lesions. Clinical Liver Disease, 2021, 17, 119-124.	2.1	3
8	Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy. Clinical Journal of Gastroenterology, 2021, 14, 1718-1724.	0.8	16
9	Imaging Diagnosis of Hepatocellular Carcinoma. Clinics in Liver Disease, 2020, 24, 623-636.	2.1	7
10	Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver – Update 2020 – WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultraschall in Der Medizin, 2020, 41, 562-585.	1.5	130
11	Guidelines and Good Clinical Practice Recommendations for Contrast-Enhanced Ultrasound (CEUS) in the Liver – Update 2020 WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultrasound in Medicine and Biology, 2020, 46, 2579-2604.	1.5	210
12	<i>RadioGraphics</i> Update: Contrast-enhanced US Approach to the Diagnosis of Focal Liver Masses. Radiographics, 2020, 40, E16-E20.	3.3	4
13	Time to Clarify Common Misconceptions about the Liver Imaging Reporting and Data System for Contrast-enhanced US. Radiology, 2020, 295, 245-247.	7.3	12
14	Contrast-Enhanced Ultrasound of Focal Liver Masses: A Success Story. Ultrasound in Medicine and Biology, 2020, 46, 1059-1070.	1.5	26
15	Benefits, Open questions and Challenges of the use of Ultrasound in the COVID-19 pandemic era. The views of a panel of worldwide international experts. Ultraschall in Der Medizin, 2020, 41, 228-236.	1.5	46
16	LI-RADS ancillary features on contrast-enhanced ultrasonography. Ultrasonography, 2020, 39, 221-228.	2.3	13
17	Role of US LI-RADS in the LI-RADS Algorithm. Radiographics, 2019, 39, 690-708.	3.3	45
18	Longitudinal evolution of CT and MRI LI-RADS v2014 category 1, 2, 3, and 4 observations. European Radiology, 2019, 29, 5073-5081.	4.5	20

#	ARTICLE	IF	CITATIONS
19	An update for LI-RADS: Version 2018. Why so soon after version 2017?. Journal of Magnetic Resonance Imaging, 2019, 50, 1990-1991.	3.4	19
20	<p>LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance</p>. Journal of Hepatocellular Carcinoma, 2019, Volume 6, 49-69.	3.7	93
21	Introduction to the Liver Imaging Reporting and Data System for Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 2019, 17, 1228-1238.	4.4	41
22	Gadoxetate-enhanced Abbreviated MRI for Hepatocellular Carcinoma Surveillance: Preliminary Experience. Radiology Imaging Cancer, 2019, 1, e190010.	1.6	31
23	Contrast-enhanced ultrasound approach to the diagnosis of focal liver lesions: the importance of washout. Ultrasonography, 2019, 38, 289-301.	2.3	36
24	Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma. Oncologist, 2018, 23, 586-593.	3.7	75
25	LI-RADS 2017: An update. Journal of Magnetic Resonance Imaging, 2018, 47, 1459-1474.	3.4	34
26	Evaluation of hepatocellular carcinoma transarterial chemoembolization using quantitative analysis of 2D and 3D real-time contrast enhanced ultrasound. Biomedical Physics and Engineering Express, 2018, 4, 035039.	1.2	18
27	How to perform Contrast-Enhanced Ultrasound (CEUS). Ultrasound International Open, 2018, 04, E2-E15.	0.6	222
28	LI-RADS® ancillary features on CT and MRI. Abdominal Radiology, 2018, 43, 82-100.	2.1	55
29	Focal Liver Lesions: Computer-aided Diagnosis by Using Contrast-enhanced US Cine Recordings. Radiology, 2018, 286, 1062-1071.	7.3	37
30	CEUS LI-RADS: algorithm, implementation, and key differences from CT/MRI. Abdominal Radiology, 2018, 43, 127-142.	2.1	147
31	LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents. Abdominal Radiology, 2018, 43, 75-81.	2.1	55
32	Contrast-enhanced ultrasound of the liver: technical and lexicon recommendations from the ACR CEUS LI-RADS working group. Abdominal Radiology, 2018, 43, 861-879.	2.1	85
33	Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. Radiology, 2018, 289, 816-830.	7.3	634
34	Changes in the Glycosylation of Kininogen and the Development of a Kininogen-Based Algorithm for the Early Detection of HCC. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 795-803.	2.5	48
35	American College of Radiology Contrast Enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) for the diagnosis of Hepatocellular Carcinoma: a pictorial essay. Ultraschall in Der Medizin, 2017, 38, 320-324.	1.5	84
36	Contrast Enhanced Ultrasound (CEUS) Liver Imaging Reporting and Data System (LI-RADS®): the official version by the American College of Radiology (ACR). Ultraschall in Der Medizin, 2017, 38, 85-86.	1.5	110

#	ARTICLE	IF	CITATIONS
37	Screening and Surveillance of Hepatocellular Carcinoma. Radiologic Clinics of North America, 2017, 55, 1197-1209.	1.8	28
38	2017 Version of LI-RADS for CT and MR Imaging: An Update. Radiographics, 2017, 37, 1994-2017.	3.3	185
39	Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. Journal of Clinical Investigation, 2017, 127, 2697-2704.	8.2	137
40	Contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS) 2017 "a" a review of important differences compared to the CT/MRI system. Clinical and Molecular Hepatology, 2017, 23, 280-289.	8.9	96
41	Identification of IgM as a contaminant in lectin-FLISA assays for HCC detection. Biochemical and Biophysical Research Communications, 2016, 476, 140-145.	2.1	6
42	Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trial. Therapeutic Advances in Gastroenterology, 2016, 9, 152-161.	3.2	12
43	Imaging Outcomes of Liver Imaging Reporting and Data System Version 2014 Category 2, 3, and 4 Observations Detected at CT and MR Imaging. Radiology, 2016, 281, 129-139.	7.3	85
44	Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. Molecular Cancer Therapeutics, 2016, 15, 2553-2562.	4.1	50
45	Evaluation of Liver Fibrosis Using Texture Analysis on Combined-Contrast-Enhanced Magnetic Resonance Images at 3.0T. BioMed Research International, 2015, 2015, 1-12.	1.9	28
46	Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology, 2015, 61, 1239-1250.	7.3	296
47	Hepatocellular Carcinoma Surveillance: A National Survey of Current Practices in the USA. Digestive Diseases and Sciences, 2014, 59, 3073-3077.	2.3	25
48	Effect of colesvelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: A randomized controlled trial. Hepatology, 2012, 56, 922-932.	7.3	218
49	Quantification of tumor vascularity with contrast-enhanced ultrasound for early response of transcatheter arterial chemoembolization for hepatocellular carcinoma: a report of three cases. Journal of Medical Ultrasonics (2001), 2012, 39, 15-19.	1.3	4
50	Use of Ultrasound Microbubbles for Vascular Imaging. , 2008, , 311-325.		3
51	Contrast-enhanced Ultrasound as a Predictor of Treatment Efficacy within 2 Weeks after Transarterial Chemoembolization of Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2007, 18, 57-65.	0.5	64
52	Ultrasound of the Liver. Radiologic Clinics of North America, 2005, 43, 815-826.	1.8	15
53	Noninvasive Estimation of the Pressure Gradient Across Stenoses Using Sonographic Contrast. Journal of Ultrasound in Medicine, 2004, 23, 683-691.	1.7	2
54	Carotid Arteries: Contrast-enhanced US Angiography" Preliminary Clinical Experience. Radiology, 2004, 230, 561-568.	7.3	107

#	ARTICLE	IF	CITATIONS
55	Mechanism of Parenchymal Enhancement of the Liver with a Microbubble-based US Contrast Medium: An Intravital Microscopy Study in Rats. <i>Radiology</i> , 2002, 224, 253-257.	7.3	66